Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CDAK Stock Summary
In the News
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy. According to a press release, Codiak BioSciences started the marketing process before entering into Chapter 11.
Codiak BioSciences files for bankruptcy, looks to sell off assets
Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's value. “The Board and management team have thoroughly assessed all of our strategic options and believe that this structured process represents the best possible solution for Codiak, taking into account our financial needs and the stage of our clinical and research programs,” the Massachusetts-based biopharmaceutical company said in a statement.
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety.
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CDAK Financial details
CDAK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.03 | 0.46 | 1.05 | |
Net income per share | -3.4 | -6.03 | -14.04 | -1.91 | |
Operating cash flow per share | -2.33 | -0.13 | -10.01 | -3.4 | |
Free cash flow per share | -2.97 | -0.93 | -13.33 | -3.55 | |
Cash per share | 6.78 | 6.35 | 14.04 | 3.53 | |
Book value per share | 7.02 | 1.67 | 2.3 | 2.45 | |
Tangible book value per share | 7.02 | 1.67 | 2.3 | 2.45 | |
Share holders equity per share | 7.02 | 1.67 | 2.3 | 2.45 | |
Interest debt per share | 0 | 0.75 | 10.25 | 3.01 | |
Market cap | 158.9M | 159.17M | 204.55M | 242.79M | |
Enterprise value | 140.81M | 158.42M | 178.62M | 228.83M | |
P/E ratio | -3.57 | -2.01 | -2.3 | -5.83 | |
Price to sales ratio | 0 | 410.23 | 70.17 | 10.59 | |
POCF ratio | -5.2 | -93.46 | -3.23 | -3.27 | |
PFCF ratio | -4.09 | -13.07 | -2.42 | -3.14 | |
P/B Ratio | 1.73 | 7.25 | 14.04 | 4.54 | |
PTB ratio | 1.73 | 7.25 | 14.04 | 4.54 | |
EV to sales | 0 | 408.31 | 61.28 | 9.98 | |
Enterprise value over EBITDA | -3.29 | -2.12 | -1.99 | -3.73 | |
EV to operating cash flow | -4.61 | -93.03 | -2.82 | -3.09 | |
EV to free cash flow | -3.62 | -13.01 | -2.12 | -2.96 | |
Earnings yield | -0.28 | -0.5 | -0.43 | -0.17 | |
Free cash flow yield | -0.24 | -0.08 | -0.41 | -0.32 | |
Debt to equity | 0 | 0.44 | 4.32 | 1.18 | |
Debt to assets | 0 | 0.08 | 0.42 | 0.37 | |
Net debt to EBITDA | 0.42 | 0.01 | 0.29 | 0.23 | |
Current ratio | 18.6 | 4.76 | 5.31 | 3.32 | |
Interest coverage | 0 | -267.17 | -47.7 | -25.8 | |
Income quality | 0.69 | 0.02 | 0.69 | 2 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 54.22 | 6.81 | 1.2 | |
Research and developement to revenue | 0 | 153.35 | 25.38 | 2.83 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.27 | 6.15 | 0.33 | 0.04 | |
Capex to revenue | 0 | -27 | -7.22 | -0.14 | |
Capex to depreciation | -4.82 | -3.78 | -3.8 | -0.51 | |
Stock based compensation to revenue | 0 | 18.67 | 2.43 | 0.44 | |
Graham number | 23.16 | 15.07 | 26.96 | 10.27 | |
ROIC | -0.53 | -2.58 | -0.76 | -0.51 | |
Return on tangible assets | -0.46 | -0.68 | -0.59 | -0.24 | |
Graham Net | 6.35 | -0.39 | -7.56 | -1.88 | |
Working capital | 86.16M | 74.36M | 76.11M | 63.01M | |
Tangible asset value | 92.03M | 21.95M | 14.57M | 53.51M | |
Net current asset value | 85.43M | 107K | -43.02M | -27.99M | |
Invested capital | 0 | 0.44 | 4.32 | 1.18 | |
Average receivables | 0 | 2.96M | 2.96M | 644.5K | |
Average payables | 0 | 1.5M | 2.2M | 1.93M | |
Average inventory | 0 | 1.12M | 1.12M | -644.5K | |
Days sales outstanding | 0 | 5.56K | 0 | 20.51 | |
Days payables outstanding | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0.07 | 0 | 17.79 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | -0.48 | -3.61 | -6.1 | -0.78 | |
Capex per share | -0.63 | -0.8 | -3.32 | -0.15 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0.34 | 0.57 | 0.58 | 0 | |
Net income per share | -0.97 | 0.1 | -0.35 | -0.29 | -0.68 | |
Operating cash flow per share | -0.69 | -0.96 | -0.93 | -0.65 | -0.4 | |
Free cash flow per share | -0.71 | -0.98 | -0.94 | -0.66 | -0.4 | |
Cash per share | 4.42 | 3.44 | 2.52 | 1.86 | 2.06 | |
Book value per share | 1.52 | 2.39 | 2.16 | 1.97 | 1.55 | |
Tangible book value per share | 1.52 | 2.39 | 2.16 | 1.97 | 1.55 | |
Share holders equity per share | 1.52 | 2.39 | 2.16 | 1.97 | 1.55 | |
Interest debt per share | 2.83 | 1.5 | 2.81 | 2.78 | 2.47 | |
Market cap | 364.57M | 249.24M | 140.68M | 64.78M | 19.67M | |
Enterprise value | 328.44M | 209.85M | 146.61M | 84.85M | 29.19M | |
P/E ratio | -4.2 | 27.53 | -4.51 | -2.48 | -0.29 | |
Price to sales ratio | 315.1 | 32.38 | 11.07 | 4.93 | 702.68 | |
POCF ratio | -23.83 | -11.58 | -6.75 | -4.44 | -1.95 | |
PFCF ratio | -23 | -11.4 | -6.69 | -4.39 | -1.94 | |
P/B Ratio | 10.72 | 4.66 | 2.91 | 1.46 | 0.51 | |
PTB ratio | 10.72 | 4.66 | 2.91 | 1.46 | 0.51 | |
EV to sales | 283.87 | 27.26 | 11.54 | 6.45 | 1.04K | |
Enterprise value over EBITDA | -17.01 | -22.74 | -24.31 | -15.73 | -1.86 | |
EV to operating cash flow | -21.46 | -9.75 | -7.03 | -5.81 | -2.89 | |
EV to free cash flow | -20.72 | -9.6 | -6.97 | -5.75 | -2.88 | |
Earnings yield | -0.06 | 0.01 | -0.06 | -0.1 | -0.87 | |
Free cash flow yield | -0.04 | -0.09 | -0.15 | -0.23 | -0.51 | |
Debt to equity | 1.84 | 0.7 | 1.29 | 1.39 | 1.57 | |
Debt to assets | 0.39 | 0.22 | 0.42 | 0.47 | 0.46 | |
Net debt to EBITDA | 1.87 | 4.27 | -0.98 | -3.72 | -0.61 | |
Current ratio | 4.5 | 3.32 | 6.06 | 4.66 | 4.24 | |
Interest coverage | -31.2 | 4.08 | -13.75 | -10.81 | -28.23 | |
Income quality | 0.71 | 4.18 | 2.6 | 2.15 | 0.52 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 6.21 | 1.8 | 0.53 | 0.56 | 234.39 | |
Research and developement to revenue | 13.37 | 4.27 | 1.12 | 0.97 | 387.39 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.02 | 0.01 | 0.01 | 0 | |
Capex to revenue | -0.47 | -0.04 | -0.01 | -0.01 | -0.32 | |
Capex to depreciation | -0.32 | -0.85 | -0.13 | -0.23 | -0.01 | |
Stock based compensation to revenue | 2.67 | 0.27 | 0.18 | 0.2 | 81.68 | |
Graham number | 5.77 | 2.33 | 4.11 | 3.59 | 4.87 | |
ROIC | -0.16 | 0.06 | -0.05 | -0.05 | -0.14 | |
Return on tangible assets | -0.14 | 0.01 | -0.05 | -0.05 | -0.13 | |
Graham Net | -1.17 | -1.84 | -2.01 | -2.07 | -1.74 | |
Working capital | 80.81M | 63.01M | 58.37M | 44M | 46.78M | |
Tangible asset value | 34.01M | 53.51M | 48.38M | 44.4M | 38.93M | |
Net current asset value | -20.81M | -27.99M | -31.78M | -32.3M | -34.23M | |
Invested capital | 1.84 | 0.7 | 1.29 | 1.39 | 1.57 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.89M | 1.92M | 1.68M | 1.32M | 1.54M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.64 | 0.04 | -0.16 | -0.15 | -0.44 | |
Capex per share | -0.02 | -0.01 | -0.01 | -0.01 | 0 |
CDAK Frequently Asked Questions
What is Codiak BioSciences, Inc. stock symbol ?
Codiak BioSciences, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol CDAK
What is Codiak BioSciences, Inc. stock quote today ?
Codiak BioSciences, Inc. stock price is $0.057 today.
Is Codiak BioSciences, Inc. stock public?
Yes, Codiak BioSciences, Inc. is a publicly traded company.